JPWO2021171034A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021171034A5
JPWO2021171034A5 JP2022551825A JP2022551825A JPWO2021171034A5 JP WO2021171034 A5 JPWO2021171034 A5 JP WO2021171034A5 JP 2022551825 A JP2022551825 A JP 2022551825A JP 2022551825 A JP2022551825 A JP 2022551825A JP WO2021171034 A5 JPWO2021171034 A5 JP WO2021171034A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
liquid pharmaceutical
composition according
glycopyrrolate
liquid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022551825A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023516630A (ja
JP2023516630A5 (https=
JP7781762B2 (ja
Publication date
Priority claimed from GBGB2002786.8A external-priority patent/GB202002786D0/en
Application filed filed Critical
Publication of JP2023516630A publication Critical patent/JP2023516630A/ja
Publication of JP2023516630A5 publication Critical patent/JP2023516630A5/ja
Publication of JPWO2021171034A5 publication Critical patent/JPWO2021171034A5/ja
Priority to JP2025203938A priority Critical patent/JP2026035711A/ja
Application granted granted Critical
Publication of JP7781762B2 publication Critical patent/JP7781762B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022551825A 2020-02-27 2021-02-26 エンシフェントリンおよびグリコピロレートを含む液体医薬組成物 Active JP7781762B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025203938A JP2026035711A (ja) 2020-02-27 2025-11-26 エンシフェントリンおよびグリコピロレートを含む液体医薬組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2002786.8A GB202002786D0 (en) 2020-02-27 2020-02-27 Liquid pharmaceutical composition
GB2002786.8 2020-02-27
PCT/GB2021/050496 WO2021171034A1 (en) 2020-02-27 2021-02-26 Liquid pharmaceutical composition comprising ensifentrine and glycopyrrolate

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025203938A Division JP2026035711A (ja) 2020-02-27 2025-11-26 エンシフェントリンおよびグリコピロレートを含む液体医薬組成物

Publications (4)

Publication Number Publication Date
JP2023516630A JP2023516630A (ja) 2023-04-20
JP2023516630A5 JP2023516630A5 (https=) 2024-02-29
JPWO2021171034A5 true JPWO2021171034A5 (https=) 2024-02-29
JP7781762B2 JP7781762B2 (ja) 2025-12-08

Family

ID=70278709

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022551825A Active JP7781762B2 (ja) 2020-02-27 2021-02-26 エンシフェントリンおよびグリコピロレートを含む液体医薬組成物
JP2025203938A Pending JP2026035711A (ja) 2020-02-27 2025-11-26 エンシフェントリンおよびグリコピロレートを含む液体医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025203938A Pending JP2026035711A (ja) 2020-02-27 2025-11-26 エンシフェントリンおよびグリコピロレートを含む液体医薬組成物

Country Status (25)

Country Link
US (1) US20230112220A1 (https=)
EP (2) EP4110292B1 (https=)
JP (2) JP7781762B2 (https=)
KR (1) KR20220149669A (https=)
CN (1) CN115279343A (https=)
AU (1) AU2021227456A1 (https=)
BR (1) BR112022016015A2 (https=)
CA (1) CA3166952A1 (https=)
DK (1) DK4110292T3 (https=)
ES (1) ES2970571T3 (https=)
FI (1) FI4110292T3 (https=)
GB (1) GB202002786D0 (https=)
HR (1) HRP20240288T1 (https=)
HU (1) HUE065531T2 (https=)
IL (1) IL295442A (https=)
LT (1) LT4110292T (https=)
MX (1) MX2022010014A (https=)
PH (1) PH12022552278A1 (https=)
PL (1) PL4110292T3 (https=)
PT (1) PT4110292T (https=)
RS (1) RS65330B1 (https=)
SI (1) SI4110292T1 (https=)
SM (1) SMT202400076T1 (https=)
WO (1) WO2021171034A1 (https=)
ZA (1) ZA202208763B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3142701T3 (en) 2014-05-12 2018-08-13 Verona Pharma Plc New treatment
GB202202297D0 (en) 2022-02-21 2022-04-06 Verona Pharma Plc Formulation production process
WO2024088364A1 (zh) * 2022-10-28 2024-05-02 江苏恒瑞医药股份有限公司 一种包含异喹啉酮类化合物的药物组合物及其制备方法
EP4378942A1 (en) 2022-12-02 2024-06-05 Sandoz AG Crystal form of a pde3/4 inhibitor
CN121620356A (zh) 2023-06-26 2026-03-06 维罗纳制药公司 包含恩塞芬汀的颗粒组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2208310T3 (es) 1999-03-31 2004-06-16 Vernalis Limited Derivados de pirimido(6,1-a) isoquinolin-4-ona.
GB2468073B (en) * 2008-02-26 2012-09-05 Elevation Pharmaceuticals Inc Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
EP2968313B1 (en) 2013-03-15 2018-01-31 Verona Pharma PLC Drug combination
CN110051627A (zh) * 2014-09-15 2019-07-26 维罗纳制药公司 包含rpl554的液体吸入制剂

Similar Documents

Publication Publication Date Title
JP2017528479A5 (https=)
HRP20240288T1 (hr) Tekući farmaceutski sastav koji sadrži ensifentrin i glikopirolat
HRP20211035T1 (hr) Tekuća formulacija za inhalaciju koja sadrži rpl554
EP1014993B1 (en) New use for budesonide and formoterol
JP2016028101A (ja) 非刺激性の眼科用ポビドンヨード組成物
JP4434486B2 (ja) 医薬組成物
US20100197694A1 (en) Compositions and methods for treatment of diseases and conditions with increased vascular permeability
US20100202979A1 (en) Compositions and methods for treatment of pulmonary diseases and conditions
JPWO2021171034A5 (https=)
HUE026166T2 (en) New epoprosthenol preparation and procedure
US20110244058A1 (en) Compositions and methods for treatment of pulmonary diseases and conditions
De Luca et al. Intrapulmonary drug administration in neonatal and paediatric critical care: a comprehensive review
JPWO2020074894A5 (https=)
WO2025162212A1 (zh) 一种药物组合物、器官保存液及其应用
JP5674917B2 (ja) テトラチオモリブデン酸の治療的使用
KR100706725B1 (ko) 디아미노트리플루오로메틸피리딘의 유도체를 함유하는 폐부전 치료제 또는 예방제
JPWO2020139525A5 (https=)
JP2017500345A (ja) モンテルカストまたはその医薬的に許容しうる塩を含む液体製剤およびその製造方法
WO2022007743A1 (zh) 粘膜给药剂型和其应用
RU2021109697A (ru) Фармацевтические композиции, содержащие RPL554 в HFA-134A для введения посредством ингаляции
RU2022103508A (ru) Фармацевтическая композиция, содержащая энсифентрин
NZ767295B2 (en) Liquid Inhalation Formulation Comprising RPL554
NZ729796B2 (en) Liquid inhalation formulation comprising rpl554
Stokes Effects of infection on function and development of the lung
RU2025101365A (ru) Энсифентрин (rpl-554) для снижения частоты и/или тяжести обострений хобл